Parkinson's disease Archive
-
March 13, 2014
‘Missing link’ may spur new brain disorder drugs
Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
-
November 11, 2013
Amish aid study of Parkinson genetics
Amish populations are valuable for genetic research because of their isolation, shared ancestry and homogeneous lifestyles.
-
May 6, 2013
Newsmakers: Vanderbilt’s teaching, research and patient care efforts are making an impact
These stories from the past year show how Vanderbilt is making an impact, on campus and in the world.
-
April 29, 2013
Fava beans’ impact on urine sodium
Eating fava beans increases dopamine in blood and urine, but does not stimulate urinary sodium excretion.
-
March 21, 2013
Novel push-pull action clue to brain disorders
Researchers at Vanderbilt University have discovered a new “push-pull” mechanism in the brain that one day could lead to new treatments for movement disorders such as Parkinson’s disease, as well as stress-related disorders and addiction.
-
October 18, 2012
Nobel in Chemistry reveals VU ties that bind
Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners.
-
September 21, 2012
VU, Bristol-Myers to collaborate on Parkinson’s therapies
Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.